Alector, developing immunity-based neurological disease drugs, goes public
The "immuno-neurology" company expects to raise $176 million in the offering, which it expects to close on Monday.
immuno-neurology
The "immuno-neurology" company expects to raise $176 million in the offering, which it expects to close on Monday.